Lymphocytosis and ibrutinib treatment of CLL.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).Annals of oncology : official journal of the European Society for Medical Oncology · 2017
   Guideline
2. Optimizing Ibrutinib Posology in Chronic Lymphocytic Leukemia Using a Semi-Mechanistic Pharmacometric Framework.CPT: pharmacometrics & systems pharmacology · 2025
   Article
3. Siglec-6 as a therapeutic target for cell migration and adhesion in chronic lymphocytic leukemia.Nature communications · 2024
   Article
4. A Review on Role of Inflammation in Coronavirus Disease.Endocrine, metabolic & immune disorders drug targets · 2024
   Review
5. YouTube as a platform to better understand the treatment of lymphoma using ibrutinib: a cross-sectional study.Annals of translational medicine · 2022
   Article
6. Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review.Metabolism open · 2021
   Article
7. Role of NFAT in Chronic Lymphocytic Leukemia and Other B-Cell Malignancies.Frontiers in oncology · 2021
   Review
8. A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia.Haematologica · 2020
   Article
9. Management of atypical chronic lymphocytic leukemia presenting with extreme leukocytosis.Clinical case reports · 2020
   Article
10. Ibrutinib in primary central nervous system diffuse large B-cell lymphoma.CNS oncology · 2020
    Review
11. Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).Proceedings of the National Academy of Sciences of the United States of America · 2014
    Article

Corrections and comments

• Comment on
  Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.2014

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as